- Campuses
- Info For
- Schools
- Contact Info
- Site Maps
Dermatology
Research
Faculty Research
- Smith, JL, Rapini, RP: Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream applied Once Daily 2 Days per Week for the Treatment of Actinic Keratoses on the Head, 2002 - 2004
- Stetson CL, Sharpe BA, Wells MJ, Butler DF. Randomized clinical trial comparing terbinafine and griseofulvin with evaluation of duration of therapy and contagious status of patients with tinea capitis. Funded by the Department of Dermatology, Texas Tech University Health Sciences Center
- Wells MJ, Co-investigator: "Buschke Ollendorf" genetic research with Kenneth H. Neldner, M.D, Berthold Struck, MD and Brent Shook, MD (in progress)
- Wells MJ, Primary Investigator for a Phase IIIB Clinical trial of Elidel® cream (pimecrolimus, SDZ ASM981) with tacrolimus ointment 0.1% in the treatment of atopic dermatitis in adults sponsored by Novartis. A 13-week study followed by a 24-week study to evaluate long-term safety. (Completed)
- Wells MJ, Primary investigator for a Phase III clinical trail using photodynamic treatment for multiple basal cell carcinoma, sponsored by QLT (completed)
- Wells MJ, Primary Investigator for a clinical trail to follow-up patients using Imiquimod for treatment of Actinic Keratosis, sponsored by 3M (completed)
- Wells MJ, Primary Investigator for Phase III 6 week randomized multicenter double-blind vehicle-controlled parallel-group study to investigate Elidel for treatment of hand dermatitis, sponsored by Novartis. (completed)
Resident Research
- Wells, MJ, Brackeen, A. Clinical Trial: Efficacy and safety of Elidel 1% cream in patients with mild to moderate chronic hand dermatitis: Texas Tech Health Sciences Center- 8/2004-current.
- Freed, J., Photodynamic Therapy with Verteporfin Injection for the Treatment of Multiple Basal Cell Carcinoma, Randomized, Placebo-Controlled, Multicenter Phase III Study, Co-investigator.
- Photodynamic therapy of multiple BCC with vertiporforin injection. Phase III clinical trial. Closed 2004. Co-investigators: Wells MJ, Stetson CL, Saporito F, Freed JM.
